Showing results (21-30 of 156) with videos related to

Sort By:
Pageof 16
Journal of Clinical Medicine|December 30, 2025
Prostate Artery Embolization vs. Holmium Laser Enucleation of the Prostate: A Matched Pair Analysis of Functional Outcomes and ComplicationsSimon Hannes Friedrich Leschik, Robert Große Siemer, Friedrich-Carl von Rundstedt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 11, 2022
Tailored Immunotherapy Approach With Nivolumab in Advanced Transitional Cell CarcinomaMarc-Oliver Grimm, Bernd Jürgen Schmitz-Dräger, Uwe Zimmermann, et al.
The World Journal of Men'S Health|August 31, 2016
Gigantic Suprapubic Lymphedema: A Case StudyRoozbeh Tanhaeivash, Tobias Franiel, Marc-Oliver Grimm, et al.
International Journal of Molecular Sciences|May 28, 2022
Wnt/β-Catenin Signalling and Its Cofactor BCL9L Have an Oncogenic Effect in Bladder Cancer CellsRoland Kotolloshi, Mieczyslaw Gajda, Marc-Oliver Grimm, et al.
Urologie (Heidelberg, Germany)|February 9, 2026
[Treatment of non-muscle-invasive bladder cancer]Mirjam Leeder, Katharina Leucht, Maria Marx, et al.
World Journal of Urology|March 27, 2019
Utility of the EORTC risk tables and CUETO scoring model for predicting recurrence and progression in non-muscle-invasive bladder cancer patients treated with routine second transurethral resectionGuoxian Zhang, Daniel Steinbach, Marc-Oliver Grimm, et al.
Cancers|February 25, 2023
The Antithetic Roles of IQGAP2 and IQGAP3 in CancersFei Song, Qingqing Dai, Marc-Oliver Grimm, et al.
European Urology|May 17, 2025
Belzutifan in Europe: A New Targeted Therapy for Clear Cell Renal CancerCatherine Graham, Laurence Albiges, Marc-Oliver Grimm, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|January 12, 2026
Retrospective Analysis of Vesicourethral-Anastomosis Stricture/Urethral Stricture After Robotic-Assisted Laparoscopic Radical Prostatectomy With and Without RadiotherapyKinan Massouh, Katharina Leucht, Lutz Leistritz, et al.
Urologie (Heidelberg, Germany)|January 8, 2025
[Enfortumab vedotin and pembrolizumab : Management of side effects during first line combined treatment for advanced or metastatic urothelial carcinoma]Margitta Retz, Marc-Oliver Grimm, Katharina Leucht, et al.
Pageof 16